Executive Management

Jonathan Rothberg is the founder of Butterfly and has served as the Chairman of New Butterfly’s board of directors since February 2021. He previously served as Chairman of Butterfly’s board of directors from March 2014 to February 2021, Butterfly’s Chief Executive Officer from March 2014 to April 2020, and Butterfly’s President from March 2014 to April 2014. Dr. Rothberg is a scientist and entrepreneur who was awarded the National Medal of Technology and Innovation, the nation’s highest honor for technological achievement, by President Obama for inventing and commercializing high-speed DNA sequencing. Dr. Rothberg is the founder of the 4Catalyzer medical technology incubator and the founder and Chairman of its companies: Butterfly, AI Therapeutics, Inc. (formerly LAM Therapeutics, Inc.), Quantum-Si Incorporated, Hyperfine Research, Inc., Tesseract Health, Inc., Liminal Sciences, Inc. (formerly EpilepsyCo Inc.), Homodeus Inc. and 4Bionics LLC. These companies focus on using inflection points in medicine, such as deep learning, next-generation sequencing, and the silicon supply chain, to address global healthcare challenges. Dr. Rothberg previously founded and served as Chairman, Chief Executive Officer, and Chief Technology Officer of Ion Torrent Systems, Inc. from 2007 to 2010, and founded and served as Chairman and Chief Executive Officer of RainDance Technologies, Inc. from 2004 to 2009. From 1999 to 2007, Dr. Rothberg co-founded and served as Chairman of ClarifI, Inc., and from 1999 to 2006, he founded and served as Chairman, Chief Executive Officer and Chief Technology Officer of 454 Life Sciences Corporation. With 454 Life Sciences, Dr. Rothberg brought to market the first new way to sequence genomes since Sanger and Gilbert won the Nobel Prize for their method in 1980. With 454’s technology, Dr. Rothberg sequenced the first individual human genome, and with Svante Paabo he initiated the first large-scale effort to sequence ancient DNA (The Neanderthal Genome Project). Prior to 454 Life Sciences, Dr. Rothberg founded and served as Chairman and Chief Executive Officer of CuraGen Corporation from 1993 to 2004. His contributions to the field of genome sequencing include the first non-bacterial cloning method (cloning by limited dilution) and the first massively parallel DNA sequencing method (parallel sequencing by synthesis on a single substrate), concepts that have formed the basis for all subsequent next generation sequencing technologies. Dr. Rothberg is an Ernst and Young Entrepreneur of the Year, is the recipient of The Wall Street Journal’s First Gold Medal for Innovation, SXSW Best in Show, Nature Methods First Method of the Year Award, the Connecticut Medal of Technology, the DGKL Biochemical Analysis Prize, and an Honorary Doctorate of Science from Mount Sinai. Dr. Rothberg is a member of the National Academy of Engineering, the Connecticut Academy of Science and Engineering, is a trustee of Carnegie Mellon University and an Adjunct Professor of Genetics at Yale University. Dr. Rothberg received his Ph.D., M.Phil., and M.S. in biology from Yale University and his B.S. in chemical engineering from Carnegie Mellon University. Dr. Rothberg’s qualifications to serve on New Butterfly’s board of directors include his significant scientific, executive and board leadership experience in the technology industry, as well as his knowledge of Butterfly’s business as Butterfly’s founder and former Chief Executive Officer.

Heather Getz is the Chief Financial Officer at Butterfly Network, Inc., where she oversees all aspects of corporate finance, investor relations and accounting. Previously, Getz was Executive Vice President and Chief Financial and Administrative Officer at BioTelemetry, Inc., a publicly traded remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care.

Heather has 25 years of experience spanning both public and private companies, with a strong background in the digital health and medical device space. She has a history of contributing to the creation of long-term company value, driving operational excellence, and accelerating profitability. During her tenure at BioTelemetry, the company saw an increase in market capitalization of over $2.5 billion, culminating with a sale to Royal Philips in 2021. Before this, Heather held various financial leadership positions at companies including Alita Pharmaceuticals, VIASYS Healthcare, and Sunoco

Heather holds an M.B.A. and a B.A. in Accountancy from Villanova University. She is a certified public accountant and is a member of the American Institute of Certified Public Accountants, the Pennsylvania Institute of Certified Public Accountants and the National Investor Relations Institute. She has served on the Board of Directors of ADEA, a privately held healthcare company based in Sweden from 2018 to 2021. In 2013, Getz was recognized by the Philadelphia Business Journal and Drexel University’s LeBow College of Business as a CFO of the Year, Large Company Finalist. Getz was also a co-facilitator of BioTelemetry’s leadership program offered to high-potential employees and senior leaders in the organization.

Larry Weiss is the Chief Legal Officer and Corporate Secretary at Butterfly Network, Inc. where he oversees and is responsible for all legal and compliance matters. Previously, Larry served as Senior Vice President and Chief Legal Officer at Emulate, a leading provider of next-generation in vitro models.

Larry has over 20 years of experience managing Legal, Compliance and Government Affairs in the medical devices, life sciences and technology industries.

Prior to Emulate, Larry served as Senior Vice President, General Counsel and Corporate Secretary for Analog Devices, Inc., a publicly traded global semiconductor company based in Boston, managing the Legal, Compliance and Government Affairs function.

Before this, he worked for 20 years in a series of roles for global medical device companies Medtronic, Covidien and Tyco Healthcare, including in the roles of Medtronic Group General Counsel for the Minimally Invasive Therapies Group, General Counsel for the Covidien Surgical Solutions business unit and serving as Covidien’s first Chief International Counsel supervising all international legal matters for the company. In these roles, Larry has managed mergers and acquisitions, strategic transactions, intellectual property strategy and litigation, international growth strategies, global compliance issues and corporate transformation projects.

Prior to joining Tyco Healthcare, Larry worked in the corporate department of Goodwin Procter & Hoar in Boston.

Larry is a graduate of Boston University’s School of Law and Tulane University. He serves on the Boards of Directors of Greater Boston Legal Services, the Northeast Chapter of the Association of Corporate Counsel and the New England Law Foundation.

Darius is Chief Strategy Officer and Chief Business Development Officer at Butterfly Network (MedTech Unicorn), where he helps lead the company's fundraising, global health, commercial and strategic efforts. In 2018, and while a student at HBS, Darius raised $250 million dollars for Butterfly Network - the largest medical imaging raise in history.

Prior to coming to HBS, Darius was Head of Trading at Birch Grove Capital, a Global Cross-Asset Hedge Fund which manages over $1BN. In this capacity he was responsible for all trading across Credit, Equities, Convertibles, Bank Debt and Commodities as well as helping the CIO in risk and portfolio management.

Prior to Birch Grove, Darius built the Cross Asset Special Situations Desk at Morgan Stanley, where he was amongst the firm’s youngest hires. In this role, he was responsible for sourcing and structuring over $1BN in banking transactions and acted as the Firm’s specialist on Argentina during the default proceedings.

Darius holds a MBA from Harvard Business School and a B.S from Duke University, where he studied Neuroscience and Psychology, and worked for Dan Ariely, one of the world’s foremost Behavioral Economists. He speaks five languages, holds three passports and has lived and worked in New York, London, Buenos Aires and São Paulo.

Tamara Dillon is the Chief People Officer at Butterfly Network, Inc. where she oversees and leads all aspects of the company’s People department including its approach to culture, talent acquisition, learning and development.

Prior to this, Tamara worked at Akebia Therapeutics where she was Senior Vice President of Human Resources and Chief People Officer. During her almost eight years at Akebia she played an integral role in building the company and was instrumental in developing their leadership team and culture. She was also Chief of Staff to the CEO as well as leading their DEI and Patient Advocacy functions.

She served as Head of Human Resources, Global Discovery Chemistry at Novartis Institutes for BioMedical Research, where she was responsible for all aspects of human resources across five sites and four countries.

Previously, she held several key roles at Genzyme, a Sanofi Company, including Senior Director Human Resources, Global Research and Development. In this global leadership role, Ms. Dillon worked closely with the senior management team to ensure that overall business strategies were translated into impactful and effective human resources programs.

Dr. John Martin is the Chief Medical Officer of Butterfly Network, a transformational medical device company that is democratizing medical imaging across the globe.

Dr. Martin completed a residency in general surgery and vascular surgery at Parkland Memorial Hospital in Dallas Texas. He is board certified in vascular surgery and a Fellow of the American College of Surgeons. He served in the United States Air Force for 7 years first as a corpsman and then after completing medical school and training he returned as a Surgeon.

He has held multiple positions throughout his career including Chief of Vascular Surgery and Director of Heart and Vascular Services at Anne Arundel Medical Center, President of Cardiology Associates, and Vice President of Physician Operations for MedStar Medical Group.

He is the founder and President of the Heart Health Foundation and the award-winning Dare to CARE Program. He is the author of multiple peer reviewed papers and book chapters, holds several patents and developed clinical software used across the country. An often-requested speaker, his most recent events include Wall Street Journal Live in Hong Kong and TedMed.

Dr. Stoica is the Chief Technology Officer at Butterfly Network. In this role, he leads the company’s technology and product development operations. Prior to Butterfly Network, Dr. Stoica was the Chief Technology Officer for BioTelemetry, a leading remote cardiac monitoring company serving over 1 million patients a year.

At BioTelemetry Dr Stoica was responsible for hardware and software product development, product management, enterprise, and product information technology, as well as product manufacturing and distribution. In 2021 BioTelemetry was acquired by Philips.

Prior to BioTelemetry, Dr. Stoica held various leadership positions at IQVIA, with the last position as Senior Vice President, Systems Development. In that role he led the development of the company’s Data Cloud Platform. The Data Cloud supported the largest data brokerage business in the world, operated one of the top 20 private data clouds, it had over 120,000 data suppliers, and it managed more than 1 million data streams in over 100 countries.

Dr. Stoica’s other appointments include information technology positions in the health IT industry as well as research and teaching positions in academia. Dr. Stoica holds a Ph.D. in Computer Science and Engineering from the University of South Carolina.

Niki Montgomery is the SVP, Commercial Development at Butterfly Network. Niki Montgomery is an accomplished leader with over 25 years of experience in marketing, product development, channel management, finance, quality control and operations. Niki joined Butterfly in 2022 and leads the company in the organizing, planning, and implementation of international expansion, marketing activities, and adjacent value streams.

Prior to Butterfly, Niki was the Global Vice President for the combined 3M and KCI Wound Care portfolios where she integrated a team of 42 full time marketing & services staff located in the US and UK. In response to the COVID-19 pandemic, Niki led her team in creating and executing response and recovery plans, as well as ensuring continuity of patient care and growing market share throughout the pandemic.

Prior to this role Niki held various leadership positions within 3M’s Medical Solutions Division, supporting Global teams for multiple business segments including Vascular Access Solutions Business, and Hospital/ICU. As part of the leadership team, she led the development and execution of a country readiness and prescriptive portfolio model for the global division. Niki also worked in the Oral Care Division, where she first led the Crown & Bridge Materials global business and then the entire Indirect Solutions (Prosthodontics) global business team.

In 2007, Niki served in a marketing leadership role at a start-up Traffic Technology company before returning to 3M in 2011 as the Global Marketing Manager for the Pathogen product portfolio, which included responsibility for launching the new 3M™ Molecular Detection System into 36 countries during the first year. In 2013, Niki became the Global Business Team leader for the newly formed Pathogens Detection Solutions Business Team for 3M Food Safety.

Niki holds a Executive MBA and a B.A. in Accounting from the University of Minnesota, Carlson School of Management. She began her career in Finance at 3M, where she worked as a corporate auditor, plant accountant and financial analyst, followed by roles of increasing responsibility and leadership within the Sales & Marketing function.